

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

ANNOUNCEMENT

PRINCIPAL FINANCIAL INFORMATION OF SHANDONG WEIGAO ORTHOPAEDIC DEVICE COMPANY LIMITED FOR THE YEAR ENDED 31 DECEMBER 2021

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) dated 29 March 2022 (the “**Announcement**”) in relation to the audited financial information of Shandong Weigao Orthopaedic Device Company Limited (“**Weigao Orthopaedic**”), a subsidiary of the Company for the year ended 31 December 2021 and whose shares are listed on the science and technology innovation board on the Shanghai Stock Exchange (stock code: 688161).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal audited financial data of Weigao Orthopaedic for the year ended 31 December 2021 as set out in the Announcement.

* *For identification purpose only*

PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF WEIGAO ORTHOPAEDIC

(1) Principal accounting data

Unit and Currency: RMB

Principal financial data	2021	2020	Yoy change (%)	2019
Operating revenue	2,153,547,035.04	1,823,776,334.04	18.08	1,574,008,097.20
Net profit attributable to shareholders of the listed company	690,318,387.81	558,404,672.79	23.62	441,673,862.73
Net profit after deduction of nonrecurring profit or loss attributable to shareholders of the listed company	678,007,610.19	538,981,928.78	25.79	435,070,170.64
Net cash flows from operating activities	788,251,164.57	644,123,438.97	22.38	534,154,274.53
	At the end of 2021	At the end of 2020	Yoy change (%)	At the end of 2019
Net assets attributable to shareholders of the listed company	4,531,539,606.55	2,453,797,254.33	84.67	1,871,762,105.99
Total assets	5,403,274,095.25	3,174,596,918.79	70.20	3,212,624,550.47

(2) Principal financial indicators

Principal financial indicators	2021	2020	Yoy change (%)	2019
Basic earnings (RMB per share) per share	1.82	1.56	16.67	1.33
Diluted earnings (RMB per share) per share	1.82	1.56	16.67	1.33
Basic earnings per share after deducting non-recurring profit or loss (RMB per share)	1.79	1.5	19.33	1.31
Weighted average return on net assets (%)	19.76	25.78	Decreased by 6.02 percentage points	22.64
Weighted average return on net assets after deducting nonrecurring profit or loss (%)	19.41	24.88	Decreased by 5.47 percentage points	22.3
Proportion of R&D investment in operating revenue (%)	5.63	4.52	Increased by 1.11 percentage points	4.71

By Order of the Board

Shandong Weigao Group Medical Polymer Company Limited

Long Jing

Chairman

Weihai, Shandong, the PRC, 29 March 2022

As at the date hereof, the Board comprises of:

Mr. Long Jing (*Executive Director*)

Mr. Cong Rinan (*Executive director*)

Mr. Tang Zhengpeng (*Non-executive Director*)

Mr. Chen Lin (*Non-executive Director*)

Mr. Lian Xiaoming (*Non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)

Mrs. Fu Mingzhong (*Independent non-executive Director*)

Mrs. Wang Jinxia (*Independent non-executive Director*)